Team

Petra is the Chief Scientific Officer at Oncimmune Germany GmbH, a position she has held since 2023. Petra led the Medical Research department of Protagen AG from 2012 and on the acquisition of Protagen AG by Oncimmune in 2019 Petra assumed the role of Director of Medical Research. Prior to joining Oncimmune, she held senior management positions at Proteome Sciences (Frankfurt, Germany) and Digilab BioVisioN (Hanover, Germany), where she led autoimmune disease, diabetes, and oncology biomarker development programmes. In her previous roles, Petra worked for biomarker discovery companies specializing in proteomics and gained extensive experience in omics-type biomarker programmes, collaborating with pharma, biotech, and academic partners to address the need for biomarkers throughout all phases of clinical drug development. Throughout her career, she has specialised in B cell-mediated immunity, antigen presentation, autoimmunity, and allergy. She received her PhD (Dr. rer. nat.) from the University of Bielefeld (Germany) and was a Postdoctoral Fellow at the Laboratory of Molecular Biology (LMB) in Cambridge, UK.

Hans-Dieter is an expert in biomarkers and bioinformatics, boasting over 25 years at the forefront of the field. As the Chief Technical Officer (CTO) at Oncimmune, he leads groundbreaking initiatives in autoimmunity, cancer research and diagnostics technology. He began his career after earning his Diploma in Biochemistry in Hannover, Germany, in 1991, followed by a PhD under Prof. Forssmann in 1994 at the Lower Saxony Institute of Peptide Research, specializing in bioactive peptides. In 1996, he joined BioVision, significantly advancing the nascent field of Peptidomics by integrating mass spectrometry with pioneering data science techniques. Since 2008, Hans-Dieter has led the Proteomics Operations at Proteome Sciences in Frankfurt. He did his Habilitation in 2003, and is a visiting Professor at Paris-Lodron University in Salzburg, Austria. His prolific academic output includes over 50 influential publications, numerous book chapters, and several patents. He was a member of numerous EU grants and a reviewer for the European Union. His research focuses on biomarkers and data mining of highly-dimensional data using cutting-edge multiplex technologies.

Since joining Protagen Diagnostics in Germany in 2013—later part of Oncimmune—he has transformed the technology to a world-class standard by integrating state-of-the-art Luminex technologies, advanced data science methodologies, and rigorous quality control systems.

Jamie is a MIT-trained mechanical engineer focused on transforming health and disease discovery through engineering and individual empowerment. He entered biomedicine after his brother was diagnosed with ALS in 1999, a personal turning point that has guided his work ever since.

Prior to Alden Scientific, Jamie founded the ALS Therapy Development Institute, PatientsLikeMe, and AOBiome. He also serves on Michael Porter’s board at ICHOM, developing global health outcome standards. His work has been featured in The New Yorker, 60 Minutes, TEDMED, Pulitzer Prize winner Jonathan Wiener’s His Brother’s Keeper, and the Sundance award-winning documentary So Much So Fast.

Eva Maria is a passionate business builder and investor with a deep personal interest in distributing predictive, individualized healthcare. Prior to joining Alden Scientific, Eva Maria spent 20+ years in the investment industry in company analysis, portfolio management, and scaling large private funds. She joined Alden Scientific first as an investor, but after seeing the world through the Alden lens, she could not unsee it. In 2024, she left her fund to dedicate herself full-time to operationalizing and scaling the company’s technology.

Eva Maria has served on several nonprofit and for-profit boards, and has a particular interest in women’s reproductive health, social services, and social justice. She can often be found picking up shifts at her local food and clothing bank.

Eva Maria completed an individualized major (BA) from the University of Connecticut, graduating in less than two years, and holds the Chartered Financial Analyst designation.